{"id":3762,"date":"2018-12-13T13:20:15","date_gmt":"2018-12-13T07:50:15","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=3762"},"modified":"2021-07-24T12:57:09","modified_gmt":"2021-07-24T07:27:09","slug":"business-cocktail-19","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-19","title":{"rendered":"Lilly remunerates AC Immune; Akero adds $70M; Ra Pharma $100M"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>Lilly remunerates AC Immune USD 81 Million for preclinical Alzheimer\u2019s drug<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Eli Lilly<\/strong> has\u00a0remunerated\u00a0<strong>USD 81 million<\/strong> upfront for the global rights to <strong>AC Immune<\/strong>\u2019s tau aggregation inhibitors in <a href=\"https:\/\/www.delveinsight.com\/report-store\/alzheimers-disease-ad-market\"><strong>Alzheimer\u2019s disease<\/strong><\/a>. The agreement provides Lilly ownership of a small molecule that has prevented tau aggregation in preclinical models. Switzerland based AC Immune\u2019s tau program has sought to discover and develop small molecules that disaggregate tau proteins and prevent the misfolded proteins from aggregating in the first place. AC Immune targets to decrease pathological tau aggregates and thereby improve the memories of people with Alzheimer\u2019s and other diseases.<\/p>\n<p style=\"text-align: justify;\"><strong>Akero Therapeutics adds another USD 70 Million <\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Akero Therapeutics<\/strong> has\u00a0added\u00a0<strong>USD 70 million<\/strong> in its <strong>B round<\/strong> that will push its lead asset, a treatment for <a href=\"https:\/\/www.delveinsight.com\/report-store\/nonalcoholic-steatohepatitis-nash-market\"><strong>nonalcoholic steatohepatitis (NASH<\/strong>)<\/a> that is licensed from <strong>Amgen<\/strong>. Akero will also build out its metabolic disease pipeline and boost its manufacturing capabilities.\u00a0Akero\u2019s lead asset, <strong>AKR-001<\/strong>, is an analogue of long-acting <strong>fibroblast growth factor 21 (FGF21)<\/strong>, a hormone involved in regulating metabolism and signalling in the body. But native FGF21 has a short half-life, which is only about half an hour and would require frequent dosing.<\/p>\n<p style=\"text-align: justify;\"><strong>Ra Pharma records USD 100 Million round <\/strong><\/p>\n<p style=\"text-align: justify;\">With a phase 2 win for its lead drug <strong>zilucoplan<\/strong> in rare disease <a href=\"https:\/\/www.delveinsight.com\/report-store\/myasthenia-gravis-market\"><strong>myasthenia gravis (MG)<\/strong><\/a>, Cambridge, Massachusetts-based <strong>Ra Pharma<\/strong> has filed a public funding round. Ra Pharma has stated top-line results, apprising regarding a daily subcutaneous dose of the complement C5 inhibitor drug results in an important reduction in symptom scores in patients with MG compared to placebo.<\/p>\n<p style=\"text-align: justify;\">\n","protected":false},"excerpt":{"rendered":"<p>Lilly remunerates AC Immune USD 81 Million for preclinical Alzheimer\u2019s drug Eli Lilly has\u00a0remunerated\u00a0USD 81 million upfront for the global rights to AC Immune\u2019s tau aggregation inhibitors in Alzheimer\u2019s disease. The agreement provides Lilly ownership of a small molecule that has prevented tau aggregation in preclinical models. Switzerland based AC Immune\u2019s tau program has sought [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3742,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[2314,2315,72,831,228,2317,2316,2318],"industry":[17225],"therapeutic_areas":[17240,17239,17245,17234],"class_list":["post-3762","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-ac-immune","tag-akero-therapeutics","tag-alzheimers-disease","tag-amgen","tag-eli-lilly","tag-myasthenia-gravis-mg","tag-nonalcoholic-steatohepatitis-nash","tag-ra-pharma","industry-pharmaceutical","therapeutic_areas-endocrinology-and-metabolic-disorders","therapeutic_areas-gastroenterology","therapeutic_areas-neurology","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Lilly -AC Immune deal; Akero raises $70M; Ra Pharma files $100M round<\/title>\n<meta name=\"description\" content=\"Eli Lilly has\u00a0remunerated\u00a0USD 81 million upfront for the global rights to AC Immune\u2019s tau aggregation inhibitors in.............\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-19\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lilly -AC Immune deal; Akero raises $70M; Ra Pharma files $100M round\" \/>\n<meta property=\"og:description\" content=\"Eli Lilly has\u00a0remunerated\u00a0USD 81 million upfront for the global rights to AC Immune\u2019s tau aggregation inhibitors in.............\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-19\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-12-13T07:50:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/12\/09023957\/pharma-money.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"3000\" \/>\n\t<meta property=\"og:image:height\" content=\"1575\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Lilly -AC Immune deal; Akero raises $70M; Ra Pharma files $100M round","description":"Eli Lilly has\u00a0remunerated\u00a0USD 81 million upfront for the global rights to AC Immune\u2019s tau aggregation inhibitors in.............","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-19","og_locale":"en_US","og_type":"article","og_title":"Lilly -AC Immune deal; Akero raises $70M; Ra Pharma files $100M round","og_description":"Eli Lilly has\u00a0remunerated\u00a0USD 81 million upfront for the global rights to AC Immune\u2019s tau aggregation inhibitors in.............","og_url":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-19","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-12-13T07:50:15+00:00","article_modified_time":"2021-07-24T07:27:09+00:00","og_image":[{"width":3000,"height":1575,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/12\/09023957\/pharma-money.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-19","url":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-19","name":"Lilly -AC Immune deal; Akero raises $70M; Ra Pharma files $100M round","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-19#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-19#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/12\/09023957\/pharma-money.jpg","datePublished":"2018-12-13T07:50:15+00:00","dateModified":"2021-07-24T07:27:09+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Eli Lilly has\u00a0remunerated\u00a0USD 81 million upfront for the global rights to AC Immune\u2019s tau aggregation inhibitors in.............","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/business-cocktail-19"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-19#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/12\/09023957\/pharma-money.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/12\/09023957\/pharma-money.jpg","width":"3000","height":"1575","caption":"alzheimer's"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/12\/09023957\/pharma-money-300x158.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">AC Immune<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Akero Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Alzheimer\u2019s disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Amgen<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Eli Lilly<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">myasthenia gravis (MG)<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">nonalcoholic steatohepatitis (NASH<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Ra Pharma<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">AC Immune<\/span>","<span class=\"advgb-post-tax-term\">Akero Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">Alzheimer\u2019s disease<\/span>","<span class=\"advgb-post-tax-term\">Amgen<\/span>","<span class=\"advgb-post-tax-term\">Eli Lilly<\/span>","<span class=\"advgb-post-tax-term\">myasthenia gravis (MG)<\/span>","<span class=\"advgb-post-tax-term\">nonalcoholic steatohepatitis (NASH<\/span>","<span class=\"advgb-post-tax-term\">Ra Pharma<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Dec 13, 2018","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Dec 13, 2018 1:20 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3762","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=3762"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3762\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/3742"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=3762"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=3762"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=3762"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=3762"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=3762"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}